CureVac Announces Extraordinary Meeting for Merger with BioNTech
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CureVac ( (CVAC) ) is now available.
On October 24, 2025, CureVac N.V. announced an extraordinary general meeting of shareholders scheduled for November 25, 2025, to discuss a merger proposal with BioNTech SE. The agenda includes a legal merger where CureVac will merge into CureVac Merger B.V., with BioNTech acquiring ordinary shares in exchange for American Depositary Shares. This merger is part of a strategic reorganization aimed at enhancing CureVac’s market positioning and operational capabilities.
The most recent analyst rating on (CVAC) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s strong financial performance and attractive valuation are the primary drivers of its stock score. The company’s solid balance sheet and profitability metrics provide a stable foundation, while the low P/E ratio indicates potential undervaluation. Technical analysis suggests a neutral to slightly bullish trend, supporting the overall positive outlook.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a biopharmaceutical company based in Tübingen, Germany, specializing in the development of mRNA-based medicines. The company focuses on the creation of vaccines and therapeutics for infectious diseases, oncology, and rare diseases.
Average Trading Volume: 515,775
Technical Sentiment Signal: Sell
Current Market Cap: $1.21B
Find detailed analytics on CVAC stock on TipRanks’ Stock Analysis page.
